S&P Equity Research Downgrades Barr Pharmaceuticals (BRL) to Hold
Tweet Send to a Friend
S&P Equity Research downgrades Barr Pharmaceuticals (NYSE: BRL) from Buy to Hold.
S&P analyst, H. Saftlas, says, "Q1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
S&P analyst, H. Saftlas, says, "Q1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
